SMV5: Dr. Michael Triplett, CEO of Myonexus Therapeutics on its sale to Sarepta
Failed to add items
Add to Cart failed.
Add to Wish List failed.
Remove from wishlist failed.
Adding to library failed
Follow podcast failed
Unfollow podcast failed
SMV5: Dr. Michael Triplett, CEO of Myonexus Therapeutics on its sale to Sarepta
-
Narrated by:
-
By:
About this listen
This episode of the SmartMoney Ventures Podcast features Dr. Michael Triplett, CEO of Myonexus Therapeutics who, along with co-founder Dr. Louise Rodino-Klapac, successfully completed a 9 figure exit event before securing Series A financing.
The story illustrates how successful tech transfer and strategic positioning resulted in the establishment of a new Gene Therapy Center of Excellence creating over 100 new jobs while transforming Muscular Dystrophy patient treatments.
Prior to co-founding Myonexus, Michael held leadership positions at Proctor & Gamble, Battelle Memorial Institute and Ventaira Pharmaceuticals among others.
In this episode, you will learn:
- How to get a 9 figure exit before your Series A financing
- How Technology Transfer is transforming the Heartland Region
- Why resilience is a big part of entrepreneurial psychology
- Sage advice for technical & scientific founders
- How a Gene Therapy Center of Excellence was established in Central Ohio
Dr. Triplett holds both a bachelor’s degree and a Ph.D. in Chemical Engineering from THE Ohio State University graduating Summa Cum Laude.